Anemia In Elderly Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Iron supplements, Erythropoietin, Vitamin B12 supplements, Folic acid supplements), By Product Type (Tablets, Injectable), By Dosage Forms(Solid, Liquid), By Route of Administration(Oral, Parenteral), By Age (Paediatrics, Adults, Geriatrics), By Gender(Female, Male), By End-User(Hospital pharmacy, Online pharmacy, Retail pharmacy), By Prescription Type (Over-the-Counter (OTC) drugs, Prescription (Rx) drugs), By Distribution Channel (Offline, Online) and Region Forecast 2019-2030

Anemia In The Elderly Market size was valued at US$ 2,846.9 million in 2023 and is poised to grow at a CAGR of 9.1% from 2024-2030. Anemia is a condition characterized by a deficiency of red blood cells or hemoglobin in the blood, leading to reduced oxygen-carrying capacity and potential health complications. Anemia is more prevalent in the elderly due to various factors such as nutritional deficiencies, chronic diseases, and age-related changes in the bone marrow. It can be a significant health concern for this population, as it can exacerbate existing health conditions, lead to fatigue, weakness, and impaired cognitive function, and reduce overall quality of life.

The market is driven by the growing elderly population globally and increasing awareness of the importance of addressing anemia in older adults to improve their overall health and well-being. As with any healthcare market, research and development efforts continue to advance diagnostics, treatments, and interventions to better address the specific needs of this vulnerable population. The prevalence of anemia in the elderly population can vary significantly in various regions globally. For instance, according to report findings, Anemia’s prevalence rate in the elderly population is estimated to be 10% in the United States and Europe. This estimation increases further with age greater than 80 years and among hospitalized patients or residents at nursing homes. Moreover, Pharmaceutical companies develop and market drugs targeting anemia in elderly patients, and medical devices for blood testing and monitoring are also part of the market.

Key Developments

• In August 2018, Memorial Healthcare System Hollywood, Florida, United States under the sponsorship of AMAG Pharmaceuticals, Inc. conducting a phase 3 study to evaluate the safety, efficacy, and pharmacokinetics of Ferumoxytol for the treatment of iron deficiency anemia in pediatric patients with chronic kidney diseases.